Tsp1 -/- Stz Mice, A Model For Diabetes
Inventors: Nader Sheibani-Karkhaneh, Christine Sorenson
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in an improved animal model for the study of diabetic retinopathy.
Effective and non-destructive treatments are needed for diabetic retinopathy, a major cause of blindness in the United States. Thrombospondin1 (TSP1), a matricellular protein that inhibits angiogenesis in vivo and is essential for proper retinal vascular development, is dramatically down-regulated in ocular samples from diabetic rats.
Based on this observation, UW-Madison researchers have developed a line of TSP1-negative mice that provides an improved animal model for the study of diabetic retinopathy. They induced diabetes in TSP1-/- mice by injecting them with a single dose of streptozotocin to destroy their pancreatic beta cells. The resulting TSP1 -/- mice develop diabetes-associated early vasculopathies of similar severity to those observed in a previous mouse model developed by the inventors, but after a shorter duration of diabetes.
- Testing the effects of new compounds for treating diabetic retinopathy
- Mice rapidly develop vasculopathies associated with diabetes.
- Mice become useful models after three months of diabetes, avoiding issues associated with drug testing in aged mice.
- Mice develop severe non-proliferative retinopathy, which may lead to a proliferative state (the final stage of diabetic retinopathy).
For More Information About the Inventors